StreetInsider.com News Articles

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company based in Miami, has retained Lucid Capital Markets, LLC as its financial advisor to explore potential strategic opportunities, including a possible business combination, according to a company statement.

The company did not disclose the terms of the engagement or provide a timeline for any potential transaction. Longeveron noted that the exploration of strategic options may not result in any definitive transaction.

Longeveron's lead investigational product is laromestrocel (Lomecel-B), a mesenchymal stem cell therapy derived from bone marrow of adult donors. The therapy is being developed for conditions including hypoplastic left heart syndrome (HLHS) and

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

About Longeveron Inc.

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

About Longeveron Inc.

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

About Longeveron Inc.

Longeveron HLHS trial misses primary goal but shows MACE benefit

Mon, 26 Oct 2026 09:15:25 -0400

Longeveron Inc. (NASDAQ: LGVN) announced updated results from its ELPIS II Phase 2b clinical trial evaluating laromestrocel as an adjunct therapy for infants with hypoplastic left heart syndrome (HLHS), according to a company press release.

The trial, which enrolled 40 infants randomized 1:1 to laromestrocel or standard of care (SOC), did not meet its primary endpoint of change from baseline in right ventricular ejection fraction (RVEF) at 12 months. Mean RVEF decreased by 2.6 percentage points in the SOC group and 3.3 percentage points in the laromestrocel group, with no statistically significant difference between the two groups (p=0.68).

Additional analysis of pre-specified

Longeveron HLHS trial misses primary goal but shows MACE benefit

Mon, 26 Oct 2026 09:15:25 -0400

Additional analysis of pre-specified

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026

Longeveron HLHS trial misses primary endpoint, explores options

Wed, 16 Sep 2026 17:27:33 -0400

Longeveron Inc. (NASDAQ: LGVN) announced that its ELPIS II Phase 2b clinical trial evaluating laromestrocel as an adjunct treatment for hypoplastic left heart syndrome (HLHS) did not meet its primary efficacy endpoint.

The trial, which enrolled 40 infants, measured change from baseline in right ventricular ejection fraction (RVEF) at 12 months. In the intent-to-treat population, the least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336).

Exploratory as-treated analyses showed no deaths among laromestrocel-treated patients over 12 months, compared to one death in the control group. Adjudicated major adverse cardiovascular events were approximately 31% fewer in

Longeveron HLHS trial misses primary endpoint, explores options

Wed, 16 Sep 2026 17:27:33 -0400

Longeveron Inc. (NASDAQ: LGVN) announced that its ELPIS II Phase 2b clinical trial evaluating laromestrocel as an adjunct treatment for hypoplastic left heart syndrome (HLHS) did not meet its primary efficacy endpoint.

The trial, which enrolled 40 infants, measured change from baseline in right ventricular ejection fraction (RVEF) at 12 months. In the intent-to-treat population, the least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336).

Exploratory as-treated analyses showed no deaths among laromestrocel-treated patients over 12 months, compared to one death in the control group. Adjudicated major adverse cardiovascular events were approximately 31% fewer in

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron sets 1-for-10 reverse stock split effective Aug. 26

Mon, 24 Aug 2026 16:05:17 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.

The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the